Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

Clinical trial NCT01037348 · COMPLETED

Trial details

NCT number: NCT01037348
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Choroidal Neovascularisation

Start date: 2010-01-01
Primary completion: 2012-05-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.